RespireRx Pharmaceuticals (RSPI) News Today → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free RSPI Stock Alerts $0.0009 0.00 (0.00%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 1, 2024 | morningstar.comRespireRx Pharmaceuticals Inc RSPIApril 20, 2024 | seekingalpha.comRCKT Rocket Pharmaceuticals, Inc.March 20, 2024 | globenewswire.comRespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord InjuryMarch 9, 2024 | proactiveinvestors.comRespireRx Pharmaceuticals shares Preclinical Pain Relief for their Non-Opioid Lead KRM-II-81January 22, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of DirectorsJanuary 4, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic PatientDecember 11, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business DevelopmentOctober 12, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturingOctober 12, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related ServicesAugust 30, 2023 | proactiveinvestors.comPharmaceutical cannabis sales surge, clinical trials seeing broader disease focusAugust 9, 2023 | benzinga.comRespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRxAugust 9, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating CompanyJune 24, 2023 | fool.comAlnylam Pharmaceuticals (NASDAQ: ALNY)May 24, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals' Australia cannabis subsidiary inks LOI securing $3.1M investmentMay 24, 2023 | finance.yahoo.comResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development CostsMay 16, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. (RSPI)April 21, 2023 | finance.yahoo.comRespireRx collaborates with University College London to study treatment options for GRIA disordersApril 20, 2023 | proactiveinvestors.comRespireRx collaborating with University College London to study treatment options for GRIA disordersApril 5, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA DisordersApril 3, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals highlights analogs of its anti-seizure treatment in scientific publicationsApril 3, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.March 28, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals appoints Joseph Siegelbaum as independent director on its boardMarch 28, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Appointment Joseph Siegelbaum as an Independent Member of the Board of DirectorsMarch 21, 2023 | seekingalpha.comRSPI RespireRx Pharmaceuticals Inc.March 2, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals subsidiary ResolutionRX signs on iNGENu as CRO for dronabinol developmentMarch 1, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals' Australian subsidiary ResolutionRx enters services agreement with CRO iNGENuMarch 1, 2023 | finance.yahoo.comResolutionRx Ltd and RespireRx Pharmaceuticals Inc. Announce ResolutionRx’s Entry into a Services Agreement with iNGENu CRO Pty LtdFebruary 9, 2023 | proactiveinvestors.comResolutionRx announces research & development financing agreement with Radium CapitalFebruary 1, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals' Australian subsidiary inks loan agreements to advance R&D for sleep apnea treatmentFebruary 1, 2023 | finance.yahoo.comResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development CreditsJanuary 23, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals strikes second amendment to its license agreement with the University of IllinoisJanuary 23, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals establishes ResolutionRx subsidiary in AustraliaJanuary 23, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the 2nd Amendment to its License Agreement with the University of IllinoisJanuary 12, 2023 | proactiveinvestors.comRespireRX Pharmaceuticals establishes ResolutionRX in Australia to advance its cannabinoid programJanuary 12, 2023 | seekingalpha.comRespireRx sets up new Australian company to develop cannabinoid platformJanuary 12, 2023 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Establishes ResolutionRx Ltd in Australia to Develop Its Pharmaceutical Cannabinoid PlatformDecember 5, 2022 | proactiveinvestors.comRespireRx Pharmaceuticals joins NIH program to find non-opioid pain-relief mechanisms to combat addictionDecember 5, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical DevelopmentNovember 28, 2022 | proactiveinvestors.comRespireRx Pharmaceuticals shares new letter of intent with Australian companyNovember 17, 2022 | benzinga.comRespireRx Signs LOI With Australian CRO For Dronabinol Development For Obstructive Sleep ApneaNovember 17, 2022 | proactiveinvestors.comRespireRx Pharmaceuticals signs letter of intent with Australian CRO to study drug for treating obstructive sleep apneaNovember 17, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces Entry into Letter of Intent with Australian Headquartered CRO for Dronabinol Development for Obstructive Sleep ApneaNovember 10, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces that Jeff Margolis, the Company’s CFO is presenting at the Investor Summit Q4November 7, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa Is an Invited Speaker at the 5th Meridian Drug Discovery SummitSeptember 25, 2022 | finance.yahoo.comCANbridge Pharmaceuticals Data on CAN106 to be Presented at Two ConferencesAugust 8, 2022 | proactiveinvestors.comRespireRx Pharmaceuticals says its obstructive sleep apnea drug dronabinol featured in Sleep Review magazine free e-bookAugust 8, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 EditionMay 24, 2022 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces that Dr. Arnold Lippa is an Invited Speaker at the 5th International Cannabinoid-Derived Pharmaceuticals SummitMay 17, 2022 | apnews.comProactive news headlines including Kontrol Technologies, Red Pine Exploration, RespireRx Pharmaceuticals, Kovo HealthTech and Jushi HoldingsMay 17, 2022 | proactiveinvestors.com.auRespireRx Pharmaceuticals Interim CEO talks AMPAkines in treating GRI disorders at virtual conference Get RespireRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RSPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. RSPI Media Mentions By Week RSPI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RSPI News Sentiment▼-1.000.55▲Average Medical News Sentiment RSPI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RSPI Articles This Week▼10▲RSPI Articles Average Week Get RespireRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RSPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ISCO News BLPH News CMRA News HSTO News SPRC News SBFM News EVFM News EVLO News ADTX News SXTC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:RSPI) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RespireRx Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.